Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1975 Jul;8(1):22–29. doi: 10.1128/aac.8.1.22

Therapy of Pseudomonas aeruginosa Infections with Tobramycin

Donald C Blair *, F Robert Fekety Jr *, Barbara Bruce *, Joseph Silva *, Gordon Archer *
PMCID: PMC429254  PMID: 809002

Abstract

The efficacy of tobramycin in doses of 2.7 to 5.6 mg/kg per day in 29 courses of therapy in 25 hospitalized patients with serious Pseudomonas aeruginosa infections was studied. Eighty-three percent of the P. aeruginosa strains showed zones of inhibition of 16 mm or more around a 10-μg tobramycin disk in the Bauer-Kirby disk method. Tobramycin minimal inhibitory concentration ranged from <0.05 to 1.5 μg/ml (microtiter twofold dilution method); for gentamicin they ranged from 0.05 to 6.2 μg/ml; corresponding geometric means were 0.19 and 0.49 μg/ml. Therapy was given for a median of 10 days (mean 19, range 1 to 83). The clinically satisfactory response rate for the 29 courses of therapy was 52%: critically ill, 44%; seriously ill, 50%; moderately ill, 80%. The response rates for various sites of infection were bone and cartilage, 100%; urinary tract infection, 56%; wound, 50%; respiratory tract, 67%; septicemia, 40%; abscess, 0%; burns, 44%. No adverse reactions were seen. Serum concentration (μg/ml ± standard deviation) of tobramycin determined by an agar-well plate method, were 4.81 ± 2.17 (1 h); 3.24 ± 1.43 (2 h); 2.35 ± 1.30 (4 h); and 1.40 ± 1.09 (8 h). Tobramycin appears to be as effacacious as gentamicin in the treatment of serious P. aeruginosa infections and has a theoretical advantage of lower minimal inhibitory concentration for P. aeruginosa. The data suggest that, for life-threatening infections, dosages of tobramycin may need to be increased over those used in this study.

Full text

PDF
22

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  2. Black H. R., Griffith R. S. Preliminary studies with nebramycin factor 6. Antimicrob Agents Chemother (Bethesda) 1970;10:314–321. [PubMed] [Google Scholar]
  3. Bodey G. P., Stewart D. In vitro studies of tobramycin. Antimicrob Agents Chemother. 1972 Sep;2(3):109–113. doi: 10.1128/aac.2.3.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brummett R. E., Vernon J. A., Meikle M. M. Ototoxicity of tobramycin in guinea pigs. Arch Otolaryngol. 1971 Jul;94(1):59–63. doi: 10.1001/archotol.1971.00770070095011. [DOI] [PubMed] [Google Scholar]
  5. Falco F. G., Smith H. M., Arcieri G. M. Nephrotoxicity of aminoglycosides and gentamicin. J Infect Dis. 1969 Apr-May;119(4):406–409. doi: 10.1093/infdis/119.4-5.406. [DOI] [PubMed] [Google Scholar]
  6. Greene W. H., Moody M., Schimpff S., Young V. M., Wiernik P. H. Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center. Ann Intern Med. 1973 Nov;79(5):684–689. doi: 10.7326/0003-4819-79-5-684. [DOI] [PubMed] [Google Scholar]
  7. Harwick H. J., Weiss P., Fekety F. R., Jr Application of microtitration techniques to bacteriostatic and bactericidal antibiotic susceptibility testing. J Lab Clin Med. 1968 Sep;72(3):511–516. [PubMed] [Google Scholar]
  8. Jaffe G., Ravreby W., Meyers B. R., Hirschman S. Z. Clinical study of the use of the new aminoglycoside tobramycin for therapy of infections due to gram-negative bacteria. Antimicrob Agents Chemother. 1974 Jan;5(1):75–81. doi: 10.1128/aac.5.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Klastersky J., Hensgens C., Henri A., Daneau D. Comparative clinical study of tobramycin and gentamicin. Antimicrob Agents Chemother. 1974 Feb;5(2):133–138. doi: 10.1128/aac.5.2.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Logan T. B., Prazma J., Thomas W. G., Fischer N. D. Tobramycin ototoxicity. Arch Otolaryngol. 1974 Mar;99(3):190–193. doi: 10.1001/archotol.1974.00780030198008. [DOI] [PubMed] [Google Scholar]
  11. Meyer R. D., Young L. S., Armstrong D. Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol. 1971 Dec;22(6):1147–1151. doi: 10.1128/am.22.6.1147-1151.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pennington J. E., Reynolds H. Y., Carbone P. P. Pseudomonas pneumonia. A retrospective study of 36 cases. Am J Med. 1973 Aug;55(2):155–160. doi: 10.1016/0002-9343(73)90163-0. [DOI] [PubMed] [Google Scholar]
  13. Preston D. A., Wick W. E. Preclinical assessment of the antibacterial activity of nebramycin factor 6. Antimicrob Agents Chemother (Bethesda) 1970;10:322–327. [PubMed] [Google Scholar]
  14. Shadomy S., Kirchoff C. In vitro susceptibility testing with tobramycin. Antimicrob Agents Chemother. 1972 May;1(5):412–416. doi: 10.1128/aac.1.5.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Simon V. K., Mösinger E. U., Malerczy V. Pharmacokinetic studies of tobramycin and gentamicin. Antimicrob Agents Chemother. 1973 Apr;3(4):445–450. doi: 10.1128/aac.3.4.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Traub W. H., Raymond E. A. Evaluation of the in vitro activity of tobramycin as compared with that of gentamicin sulfate. Appl Microbiol. 1972 Jan;23(1):4–7. doi: 10.1128/am.23.1.4-7.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wersäll J., Lundquist P. G., Björkroth B. Ototoxicity of gentamicin. J Infect Dis. 1969 Apr-May;119(4):410–416. doi: 10.1093/infdis/119.4-5.410. [DOI] [PubMed] [Google Scholar]
  18. Westenfelder S. R., Welling G., Madsen P. O. Efficacy and pharmacokinetics of tobramycin in patients with chronic urinary tract infections and various degrees of renal impairment. Infection. 1974;2(2):76–79. doi: 10.1007/BF01642025. [DOI] [PubMed] [Google Scholar]
  19. Wick W. E., Welles J. S. Nebramycin, a new broad-spectrum antibiotic complex. IV. In vitro and in vivo laboratory evaluation. Antimicrob Agents Chemother (Bethesda) 1967;7:341–348. doi: 10.1128/AAC.7.3.341. [DOI] [PubMed] [Google Scholar]
  20. Winters R. E., Litwack K. D., Hewitt W. L. Relation between dose and levels of gentamicin in blood. J Infect Dis. 1971 Dec;124 (Suppl):S90–S95. doi: 10.1093/infdis/124.supplement_1.s90. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES